Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and Glaucoma
Shots:
- Accure to receive an up front & is also eligible to receive an additional fees upon the achievement of development and commercial milestones along with royalties. Oculis gets an exclusive global right to develop and commercialize ACT-01 to protect & prevent damage to the optic nerve & retina
- The collaboration will combine Oculis’ ophthalmology expertise with Accure’s neuroprotective approach to treat patients with neurodegenerative diseases in ophthalmology
- ACT-01 renamed OCS-05 is being evaluated in the P-IIa (ACUITY) study for patients with acute optic neuritis. The company plans for the expansion of the program in ophthalmology with the regulatory agencies in the US, EU & China
Ref: Globe Newswire | Image: Oculis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
